Last updated: April 24, 2026
Keppra (levetiracetam) Suppliers: What can be sourced from public patent-and-product records
Keppra is a marketed brand for levetiracetam. Publicly documented supply chains for levetiracetam products typically split into (1) active pharmaceutical ingredient (API) manufacturers and (2) drug-product/packaging supply (contract manufacturing and secondary packaging). Patent records for levetiracetam and the Keppra product support that Keppra is supplied through a network of specialized manufacturing and packaging firms rather than a single universal supplier.
Who are the named suppliers for Keppra or levetiracetam in public product records?
In practice, the “supplier” term for Keppra resolves to one or more of the following supply roles, each showing up in different public documents (drug labels, marketing authorizations, and filings for solid oral tablets/oral solution equivalents):
- API manufacturers (levetiracetam synthesis and purification)
- Finished-dose manufacturers (tableting, film coating, blending)
- Packers and secondary packaging sites
- License holders/marketing authorizations tied to a regional MAH (marketing authorization holder)
Public sources that commonly list these entities include:
- Regulatory product databases (by country: applicant/MAH, manufacturing sites)
- Drug labels and leaflets (often list “manufactured for” and the manufacturing/packaging address)
- Patent family assignee records tied to levetiracetam development and process work (used to triangulate origin, not necessarily current GMP supply)
Because “supplier” can mean different roles, the most defensible procurement view is to map supply by GMP site (API vs finished dose) rather than by brand-level references.
What does the patent record indicate about supply parties?
Patent families covering levetiracetam (and related process inventions) typically name:
- Original inventors and assignees tied to the chemical entity and early process work
- Subsequent process improvements assigned to different chemical/process owners
For Keppra specifically, the key business implication from patent families is that API supply is not confined to one synthesis route owner. Multiple independent process patents increase the chance that commercial supply can be sourced from multiple API manufacturers who license or design-around the patented steps.
Who is the current marketing authorization/brand supplier behind Keppra?
Keppra’s brand owner and regional marketing authorization holder is UCB (UCB Pharma), which controls the brand authorization and typically contracts manufacturing and packaging to multiple GMP sites. That means “Keppra supplier” at the brand level is UCB, but manufacturing supply is multi-site.
How to read “supplier” in procurement terms for Keppra
Procurement diligence for Keppra should treat “suppliers” as a matrix:
| Supply role |
What to source |
Where it shows up publicly |
| API |
Levetiracetam API |
Regulatory API manufacturer sites (per product monograph/authorization) |
| Finished dose |
Keppra tablets or oral solution drug product |
Regulatory manufacturing sites and label “manufactured by/for” text |
| Packaging |
Blistering, bottle fill, cartons, secondary packaging |
Label/leaflet packaging site lines |
| MAH/brand holder |
UCB or regional affiliate |
MAH field in regulatory approval documentation |
What suppliers exist for levetiracetam (Keppra’s API) and the finished product?
Publicly visible supply lists differ by geography and by strength/format (IR tablets vs extended release where applicable, oral solution vs tablets). The most reliable supplier mapping requires country-specific product pages, because the same brand can list different manufacturing and packaging sites across regions.
From a business standpoint, your actionable approach is:
1) Map the GMP sites used in the target region (EU member states, US label/manufacturers, UK, etc.).
2) Split API and finished product to ensure the contract covers both technical release and supply continuity.
3) Validate packaging lineage for patient-facing units (carton and blister/bottle lot correlation).
Key constraints for selecting Keppra suppliers
Keppra is a mature product, so supplier counts are usually higher than for new molecular entities. However, procurement risk concentrates in:
- GMP continuity at the finished-dose site (shortages commonly originate at bottling/packing capacity or coating/tableting lines)
- API supply stability (levetiracetam API synthesis and purification capacity constraints)
- Regulatory site approval status in the specific market
- Holding/pre-shipment controls for clinical-grade vs commercial-grade batches (if your use case is non-commercial procurement)
Key Takeaways
- Keppra (levetiracetam) is supplied through multi-site GMP manufacturing and packaging, with UCB as brand/MAH at the authorization level and different contract manufacturers per region.
- “Suppliers for Keppra” must be treated as API vs finished-dose vs packaging. The only procurement-grade list is the region-specific manufacturing/packaging site list from regulatory product records and labels.
- Patent records support that levetiracetam supply is not structurally tied to a single process owner, which supports multi-source API procurement options.
FAQs
-
Is UCB the supplier of Keppra manufacturing?
UCB is the brand/marketing authorization holder. Manufacturing and packaging are executed at contract GMP sites that vary by region and product form.
-
Why do “Keppra suppliers” differ by country?
The same brand can use different GMP manufacturing and packaging sites depending on regional regulatory approvals, capacity, and distribution strategy.
-
What is the difference between an API supplier and a Keppra finished-dose supplier?
An API supplier produces levetiracetam. A finished-dose supplier manufactures the Keppra tablet or oral solution using the API, plus excipients and finished-dose processing.
-
Do patents name current Keppra manufacturers?
Patent documents usually name inventors/assignees for entity and process innovations. They do not reliably list current GMP manufacturing sites for commercial supply.
-
What supplier mapping is most actionable for procurement?
A site list by GMP function (API, finished dose, packaging) tied to the specific market and product strength/form.
References (APA)
[1] UCB. (n.d.). Keppra (levetiracetam) product information and regulatory materials (brand/MAH references vary by jurisdiction).
[2] European Medicines Agency. (n.d.). EPAR and product information databases for medicinal products containing levetiracetam (manufacturing site listings vary by authorization).
[3] U.S. FDA. (n.d.). Orange Book and drug label information for levetiracetam products (manufacturer and packaging information varies by listing).
